These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 35829812)

  • 1. The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials.
    Rossi GN; Hallak JEC; Baker G; Dursun SM; Dos Santos RG
    Eur Arch Psychiatry Clin Neurosci; 2023 Feb; 273(1):129-155. PubMed ID: 35829812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between peripheral biomarkers and clinical response to IV ketamine for unipolar treatment-resistant depression: An open label study.
    Kang MJY; Vazquez GH
    J Affect Disord; 2022 Dec; 318():331-337. PubMed ID: 36070831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.
    Kojic M; Saelens J; Kadriu B; Zarate CA; Kraus C
    Curr Top Behav Neurosci; 2022; 56():141-167. PubMed ID: 35312993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antidepressant Effect of Ketamine on Inflammation-Mediated Cytokine Dysregulation in Adults with Treatment-Resistant Depression: Rapid Systematic Review.
    Sukhram SD; Yilmaz G; Gu J
    Oxid Med Cell Longev; 2022; 2022():1061274. PubMed ID: 36160713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect.
    Cui W; Ning Y; Hong W; Wang J; Liu Z; Li MD
    Mol Neurobiol; 2019 May; 56(5):3484-3500. PubMed ID: 30140973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
    Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
    Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.
    Niciu MJ; Henter ID; Luckenbaugh DA; Zarate CA; Charney DS
    Annu Rev Pharmacol Toxicol; 2014; 54():119-39. PubMed ID: 24392693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers of ketamine's antidepressant effect: An umbrella review.
    Meshkat S; Ho RC; Cao B; Teopiz KM; Rosenblat JD; Rhee TG; Di Vincenzo JD; Ceban F; Jawad MY; McIntyre RS
    J Affect Disord; 2023 Feb; 323():598-606. PubMed ID: 36521662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketamine administration in depressive disorders: a systematic review and meta-analysis.
    Fond G; Loundou A; Rabu C; Macgregor A; Lançon C; Brittner M; Micoulaud-Franchi JA; Richieri R; Courtet P; Abbar M; Roger M; Leboyer M; Boyer L
    Psychopharmacology (Berl); 2014 Sep; 231(18):3663-76. PubMed ID: 25038867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.
    Wilkinson ST; Wright D; Fasula MK; Fenton L; Griepp M; Ostroff RB; Sanacora G
    Psychother Psychosom; 2017; 86(3):162-167. PubMed ID: 28490030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ketamine for depression.
    Jelen LA; Stone JM
    Int Rev Psychiatry; 2021 May; 33(3):207-228. PubMed ID: 33569971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
    Allen AP; Naughton M; Dowling J; Walsh A; Ismail F; Shorten G; Scott L; McLoughlin DM; Cryan JF; Dinan TG; Clarke G
    J Affect Disord; 2015 Nov; 186():306-11. PubMed ID: 26275358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression: Gamma power and long-term potentiation.
    Gilbert JR; Zarate CA
    Pharmacol Biochem Behav; 2020 Feb; 189():172856. PubMed ID: 31958471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in neurotrophic signaling pathways in brain areas of the chronic mild stress rat model of depression as a signature of ketamine fast antidepressant response/non-response.
    Derosa S; Misztak P; Mingardi J; Mazzini G; Müller HK; Musazzi L
    Prog Neuropsychopharmacol Biol Psychiatry; 2024 Jan; 128():110871. PubMed ID: 37793481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
    Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
    J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
    Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
    J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guanosine as a promising target for fast-acting antidepressant responses.
    Camargo A; Rodrigues ALS
    Pharmacol Biochem Behav; 2022 Jul; 218():173422. PubMed ID: 35732211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomic biomarkers for (R, S)-ketamine and (S)-ketamine in treatment-resistant depression and healthy controls: A systematic review.
    Kumar R; Nuñez NA; Joshi N; Joseph B; Verde A; Seshadri A; Cuellar Barboza AB; Prokop LJ; Medeiros GC; Singh B
    Bipolar Disord; 2024 Jun; 26(4):321-330. PubMed ID: 38326104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain-Derived Neurotrophic Factor (BDNF) as a biomarker of treatment response in patients with Treatment Resistant Depression (TRD): A systematic review & meta-analysis.
    Meshkat S; Alnefeesi Y; Jawad MY; D Di Vincenzo J; B Rodrigues N; Ceban F; Mw Lui L; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2022 Nov; 317():114857. PubMed ID: 36194941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacology of ketamine and esketamine as rapid-acting antidepressants].
    Pavlidi P; Megalokonomou A; Sofron A; Kokras N; Dalla C
    Psychiatriki; 2021 Dec; 32(Supplement I):55-63. PubMed ID: 34990380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.